Parexel

Gene therapies for inherited retinal diseases and neovascular age-related macular degeneration (nAMD) are advancing quickly, but defining success in real-world practice remains a challenge for sponsors, clinicians, and payers. At the 2025 American Academy of Ophthalmology (AAO) meeting, Parexel’s Bharti Arya, MRCOphth, Executive Director and Therapeutic Area Head of Ophthalmology, moderated an expert panel that explored how developers can capture outcomes that matter to patients while generating the durability data that payers require. The discussion underscored why traditional tools like the MLMT are difficult to use outside controlled settings and how measures such as FST, selective BCVA use, and patient-reported function offer a more practical picture of patient benefit. Our new blog shares key takeaways from the panel and how Parexel helps sponsors design evidence packages that are meaningful, feasible, and payer-ready. https://lnkd.in/eRHH9Vq7 #GeneTherapy #Ophthalmology #RetinalDisease #AAO2025 #ClinicalResearch

How can working with data impact patient's lives? At Parexel, Statistical Programmers work with complex patient data that requires🔹The ability to apply technical knowledge to real-world scenarios🔹Adaptability to navigate sudden obstacles🔹Interpersonal skills to ensure clear communication with team members and external stakeholders - all to advance treatments for those who need it most. Meet Patrick Grimes, Associate Director, Statistical Programming, who knows that each dataset represents a life that could be changed. Learn more about Patrick and his role: https://brnw.ch/21wXUam To be notified of empowering Parexel jobs—join our Talent Community! https://brnw.ch/21wXUan

We’re looking forward to joining hematology leaders across the globe next week at #ASH2025 in Orlando! Our team will be on-site, sharing insights and presenting new research through our posters that highlight the science and expertise driving progress in hematologic care. Visit Parexel at booth #260 and schedule a meeting with our experts to learn how we can support you in bringing meaningful therapies to patients. https://lnkd.in/eJkBWp8w #ASH #Hematology

Clinical research works best when it’s rooted in community. Matthew Kratz, Principal Lead, Patient Strategy and Insights at Parexel, shares how our teams are working to bring clinical research closer to the communities we serve in this roundtable with Clinical Trials Arena. Read how Matthew and the other panelists proposed empowering patients with information that matters, supporting site investigators and strengthening trust. By meeting patients where they are, we’re advancing research that reflects the real world and drives better outcomes for all. 📖 Read the full article: https://lnkd.in/dVrbWM_r

Stay ahead of what’s next in biotech. From scientific breakthroughs to strategic shifts shaping the future of drug development, "On the Pulse" delivers expert insights, curated trends and essential updates, right in your inbox. Designed for busy professionals, our biotech newsletter distills complex developments into clear, actionable takeaways, so you’re always informed and always a step ahead. Subscribe today to stay On the Pulse: https://lnkd.in/e4su5Frb #Biotech #DrugDevelopment

The CRO market in APAC, especially in China, is undergoing exponential growth with no signs of slowing down. In an article from BioSpace, Vera Zheng, SVP, APAC Strategy and Head of Greater China at Parexel notes that, "The rapid pace of drug development in China is incredibly competitive with companies vying to get their best-in-class products through trial stages." What has changed to make China one of the fastest rising clinical trial powerhouses? ➡️New investment in APAC region ➡️Strong interest in specific therapeutic areas with large patient bases ➡️Growing base of experts Click through below to learn more from Vera about these key developments that have propelled China and the greater APAC region onto the global stage in clinical trials. Read the full article here: https://lnkd.in/enVnh_Ut Read more about how Parexel is poised to be a bridge between China and the global markets: https://lnkd.in/eXsDN_uf

Artificial Intelligence is reshaping pharmacovigilance, and this year's World Drug Safety Congress highlighted the shift from early aspirations to practical, patient-integrated strategies. During their keynote, Parexel's Sanjay Vyas and Stacy Hurt emphasized that the future of drug safety depends on moving beyond passive reporting and toward meaningful engagement powered by real-world data and AI-driven insights. This special edition of the New Medicines, Novel Insights newsletter explores how clearer communication, empowered healthcare providers and predictive technologies are redefining safety systems and creating more intuitive, human-centered approaches to reporting and monitoring. Pharmacovigilance is entering a new era where scientific rigor and human experience combine to create safer, more transparent medicines. Read the full edition to learn how Parexel is helping lead this transformation. #WorldDrugSafetyCongress #WDSC #Pharmacovigilance #DrugSafety 

Parexel was a proud sponsor of the 2025 Black Women In Clinical Research ®Conference for the third consecutive year! This event is designed to bring together professionals in the clinical research field with the mission to promote cross-cultural understanding, be a platform that leads to meaningful connections and inspire continuous improvements in healthcare. This year, 25+ Parexel colleagues attended the conference and two represented Parexel as panelists! 💜Aida Sabo (She, Her, Hers), was a participant on the panel, "Channeling Your Inner Wonder Woman. Power, Purpose, and Career Advancement". She shared her vision for more inclusive clinical trials and how leadership will be essential in building that future. 💜Deirdre Hackley Parham was a panelist for the session, "The Power in Your Mirror: Turning Your Personal SWOT into Strategy", highlighting how to reflect, self-analyze and transform those insights into opportunities for professional growth. Click through some of our favorite pictures from the event! 📸 📥Download our sustainability and impact report to see some of our recent milestones in cultivating an environment where every individual feels valued, respected and empowered to contribute fully: https://lnkd.in/eTzB9eJk

In a recent interview with Caijing Magazine, leaders Vera Zheng, Oliver Fuhrmann, and Leo Zhang discussed how Parexel is positioned to serve as a bridge between China and the global markets, leveraging deep expertise across countries to accelerate delivery of new treatments to patients. "On one hand, we help Asia-Pacific pharmaceutical companies 'go out' to conduct international-standard Chinese and global multicenter clinical trials; on the other hand, we also assist global pharmaceutical companies to 'come in' and implement global or local clinical projects in the Asia-Pacific region," said Vera. Tap through for more on the bidirectional expertise which positions Parexel as the ideal strategic partner for navigating the interconnected global biopharma landscape. ➡️ OR read the full interview here: https://lnkd.in/eXsDN_uf

Migrating safety data is a high-stakes move, and when one midsize biopharma needed to transition global safety vendors, they chose Parexel. With 10,000+ cases, 45 protocols and 3 products in scope, our experts delivered a seamless migration to a new safety database, on time and without disruption. With deep expertise and proven frameworks, our team delivered: ☑️ Strategic planning and testing ☑️ Agility to adapt mid-transition ☑️ Daily collaboration and live KPI reviews The result? A successful safety database migration supporting 30+ SDEAs, QPPV activities and global regulatory needs across clinical and post-approval programs. With Parexel, vendor transitions are backed by proven frameworks and a focus on continuity, risk mitigation and delivery. Let’s talk about how we can support your next transition. https://lnkd.in/eYMYh7nX #Safety #VendorTransition